Perioperative Management of Female Hormone Medications.
CONCLUSION: Until additional studies are performed, the risks and benefits must be weighed on an individual basis with consideration of prophylaxis when a decision is made to continue these medications in the perioperative period. Part of this decision making includes the risk of fetal harm in an unwanted pregnancy in preparation for nonobstetric surgery versus an increased risk of venous thromboembolism.
PMID: 28969534 [PubMed - as supplied by publisher]
Source: Current Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Seim LA, Irizarry-Alvarado JM Tags: Curr Clin Pharmacol Source Type: research
More News: Anesthesia | Anesthesiology | Cancer | Cancer & Oncology | Drugs & Pharmacology | Health Management | Hormonal Therapy | Hormone Replacement Therapy | Hormones | Men | Menopause | Oral Cancer | Orthopaedics | Osteoporosis | Pregnancy | Study | Thrombosis